WO2010021289A1 - トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 - Google Patents
トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 Download PDFInfo
- Publication number
- WO2010021289A1 WO2010021289A1 PCT/JP2009/064285 JP2009064285W WO2010021289A1 WO 2010021289 A1 WO2010021289 A1 WO 2010021289A1 JP 2009064285 W JP2009064285 W JP 2009064285W WO 2010021289 A1 WO2010021289 A1 WO 2010021289A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- recombinant
- avian influenza
- vaccine
- protein
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to vaccination of poultry, particularly chickens. Specifically, the present invention relates to a booster immunization material and method for poultry primed with an injection-type oil vaccine.
- influenza that infects birds is prevalent, especially in Southeast Asia, and the poultry industry in particular has suffered enormous damage (Bagchi, (2008) CMAJ, 178: 1415).
- cases of highly pathogenic strains of the H5N1 subtype have been sporadic in humans, and a pandemic as a new influenza is feared (Wright, (2008) N. Engl. J. Med., 358: 2540-2543).
- avian influenza virus countermeasures are an important issue for public health.
- immunity induction by the administration of a vaccine is effective, and therefore, in Japan, injection-type oil vaccines by intramuscular inoculation are manufactured and stockpiled.
- the immunity conferred by this vaccine can be maintained at a high level for a longer period, it can be a very effective preventive measure.
- existing means for that purpose are insufficient in terms of effectiveness, price, simplicity, and the like.
- methods for preparing a material for influenza vaccine include “vaccine and vaccine protein using Sendai virus vector (patent publication 2000-253876)” and “recombinant influenza virus for vaccine and gene therapy (patent publication 2003-528570). ) ",” Methods of developing protein vaccine and avian influenza vaccine using reverse genetic method (patent publication 2007-282636) ", etc., but neither mentions booster immunization.
- An object of the present invention is to provide an immunization material capable of maintaining a high level of immunity given by an initial immunization with an oil vaccine for a longer period of time, and to establish a simple and rational booster method.
- the present inventors made HA and NP proteins that are effective antigens for preventing avian influenza by recombinant DNA technology.
- Synthetic oligo CpG which is a mucosal adjuvant, was added to the recombinant HA antigen and recombinant NP antigen, and the oil vaccine was orally administered to chickens inoculated intramuscularly.
- antibody production was re-induced by mixing and administering the recombinant HA antigen, recombinant NP antigen and synthetic oligo CpG orally.
- the vaccine of the present invention was ineffective or weak when used for primary immunization, and was effective when used for booster immunization. That is, the present invention provides the following [1] to [10].
- An immune material comprising an avian influenza virus antigen and a mucosal adjuvant effective for oral administration.
- the immune material according to [1] wherein the avian influenza virus antigen is a recombinant HA antigen and a recombinant NP antigen.
- the present invention provides an immune material comprising an avian influenza virus antigen and a mucosal adjuvant effective for oral administration.
- the immune material of the present invention is preferably an immune material for preventing influenza.
- Influenza is a life-threatening infectious disease for patients with underlying diseases and the elderly. Recently, avian influenza caused by infecting birds is also prevalent. Among them, highly pathogenic avian influenza causes extremely high pathogenicity when infected with chickens, quails, turkeys, etc. of poultry among infections caused by influenza A virus. Highly pathogenic avian influenza is defined as an avian influenza virus that kills chickens at a high rate by intravenous inoculation, or a so-called virulent virus in which basic amino acids are continuous at the cleavage site of HA. Influenza A is classified by HA type (and NA type), but the highly pathogenic avian influenza found to date is limited to H5 and H7 subtypes. These subtype viruses may become highly toxic as infection is repeated, and vigilance is required regardless of whether they are toxic or attenuated.
- influenza viruses that do not infect humans, for example, subtypes such as H5 and H7, can infect humans and are mutated so that they can grow in humans. Viruses that have come to be equipped are called new influenza viruses. Since humans do not have immunity against these new influenza viruses, this spread of infection becomes a global pandemic, and enormous damage is expected.
- influenza virus antigen is a recombinant antigen having an influenza virus as a gene donor and means an antigen having the ability to prevent influenza infection and disease.
- influenza virus antigens already known to have influenza preventive effects include hemagglutinin (HA) antigen, neuraminidase (NA) antigen, NP (nucleoprotein) antigen, and M protein (matrix protein) antigen.
- influenza virus antigen contained in the immunity material of the present invention may be any subtype virus as long as it has an effect of preventing immune re-induction or immunity reduction by additional oral immunization.
- antigens that can be used in the present invention include (1) virus surface antigens HA and NA, and (2) virus internal structure antigens such as NP and M. It is not limited. PA, PB1, PB2, NS2 can also be used. These may be used alone or in any combination of two or more.
- influenza virus antigens contained in the immune material of the present invention are preferably HA antigens and NP antigens.
- the influenza virus antigen of the present invention is not limited to the above-mentioned antigens. As long as it is an antigen that is functionally equivalent to the HA antigen and NP antigen, a naturally occurring or artificially produced mutant antigen with altered gene sequence or amino acid sequence Are also included in the present invention.
- the antigen functionally equivalent to the HA antigen is a protein having the same antigenicity as the HA antigen.
- the antigen functionally equivalent to the NP antigen is a protein having the same antigenicity as the NP antigen.
- the influenza virus antigen contained in the immune material of the present invention is preferably a recombinant HA antigen.
- the following proteins are exemplified as the recombinant HA antigen.
- C a protein and function comprising an amino acid sequence in which one or more amino acids are substituted, deleted, inserted, and / or added in the amino acid sequence described in SEQ ID NO: 2, and comprising the amino acid sequence described in SEQ ID NO: 2 Equivalent protein;
- the influenza virus antigen contained in the immune material of the present invention is preferably a recombinant NP antigen.
- the recombinant NP antigen include the following proteins.
- A a protein comprising the amino acid sequence set forth in SEQ ID NO: 4;
- B a protein encoded by a nucleic acid comprising the coding region of the base sequence set forth in SEQ ID NO: 3;
- C a protein and function comprising an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence described in SEQ ID NO: 4, and comprising the amino acid sequence described in SEQ ID NO: 4 Equivalent protein;
- D a protein encoded by a nucleic acid that hybridizes under stringent conditions with a nucleic acid comprising the base sequence set forth in SEQ ID NO: 3 and is functional with a protein comprising the amino acid sequence set forth in SEQ ID NO: 4 Equivalent protein.
- a circular double-stranded vector in which a gene to be introduced with a mutation is cloned is made into a single strand, and a synthetic oligonucleotide having a mutation at the target site is hybridized.
- Complementary single-stranded DNA derived from a vector that has been linearized by cutting with a restriction enzyme is annealed to the circular single-stranded vector, and the gap between the synthetic nucleotide is filled with DNA polymerase and further ligated.
- the number of amino acids to be modified is typically within 50 amino acids, preferably within 30 amino acids, and more preferably within 5 amino acids (eg, 1 amino acid).
- the protein of the present invention includes a protein to which a conservative substitution has been added in the above amino acid substitution, and is functionally equivalent to a protein comprising the amino acid sequence set forth in SEQ ID NO: 2 or 4. Conservative substitution is considered to be important, for example, when substituting amino acids of domains important for protein activity. Such amino acid conservative substitutions are well known to those skilled in the art.
- amino acid groups corresponding to conservative substitutions include basic amino acids (eg, lysine, arginine, histidine), acidic amino acids (eg, aspartic acid, glutamic acid), uncharged polar amino acids (eg, glycine, asparagine, glutamine, serine, Threonine, tyrosine, cysteine), nonpolar amino acids (eg alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched amino acids (eg threonine, valine, isoleucine), and aromatic amino acids (eg tyrosine, phenylalanine) , Tryptophan, histidine) and the like. It is also conceivable to increase the activity of the protein by non-conservative substitution (for example, including a permanently activated protein).
- non-conservative substitution for example, including a permanently activated protein.
- DNA encoding the influenza virus antigen of the present invention as shown in SEQ ID NO: 1 or 3 or a fragment thereof is used as a probe, and DNA that can hybridize with this is isolated.
- DNA with high homology is selected as the base sequence, and as a result, the protein isolated may contain a protein functionally equivalent to the influenza virus antigen. Will increase.
- a highly homologous base sequence can exhibit, for example, 70% or more, preferably 90% or more homology (identity).
- the stringent conditions can be specifically exemplified by conditions such as 6XSSC, 40% formamide, hybridization at 25 ° C, and washing at 1XSSC, 55 ° C.
- the stringency depends on conditions such as salt concentration, formamide concentration, or temperature, but it is obvious to those skilled in the art to set these conditions to obtain the required stringency.
- hybridization for example, DNA encoding a homologue of an influenza virus antigen other than a protein containing the amino acid sequence shown in SEQ ID NO: 2 or 4 can be isolated.
- a protein functionally equivalent to a protein containing the amino acid sequence described in SEQ ID NO: 2 or 4 usually has high homology with the amino acid sequence described in SEQ ID NO: 2 or 4.
- High homology refers to sequence homology (identity) of at least 30% or more, preferably 50% or more, more preferably 80% or more (eg, 95% or more).
- the homology of base sequences and amino acid sequences can be performed using a homology search site using the Internet [for example, homology such as FASTA, BLAST, PSI-BLAST, and SSEARCH in Japan DNA Data Bank (DDBJ).
- search is available [For example, the homology search (Search ⁇ and Analysis) page of the Japan DNA Data Bank (DDBJ) website ;; http://www.ddbj.nig.ac.jp/E-mail/homology-j. html].
- search using BLAST can be performed in National Center for Biotechnology Information (NCBI) (for example, the BLAST page on the NCBI homepage; http://www.ncbi.nlm.nih.gov/BLAST /; Altschul, SF et al., J. Mol. Biol., 1990, 215 (3): 403-10; Altschul, SF & Gish, W., Meth. Enzymol., 1996, 266: 460-480; Altschul , SF et al., Nucleic Acids Res., 1997, 25: 3389-3402). ].
- the amino acid sequence identity in Advanced BLAST 2.1 is calculated using blastp as the program, Expect value is 10, Filter is all OFF, BLOSUM62 is used as Matrix, Gap existence cost, Per residue gap cost, and Lambda ratio Can be set to 11, 1, and 0.85 (default values), respectively, to obtain the identity value (%) (Karlin, S. and S. F. Altschul (1990) Proc. Natl. Acad. Sci. USA 87: 2264-68; Karlin, S. and S. F. Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-7).
- the recombinant antigen of the present invention is not particularly limited as long as it is suitable for oral administration, for example, an antigen expressed by recombinant DNA technology in unicellular prokaryotes such as E. coli and unicellular eukaryotes such as yeast, Antigens expressed in multicellular organisms such as insects, plants and animal cells are also included.
- animal cells for example, animal cells, plant cells, and fungal cells can be used as the host.
- Animal cells include mammalian cells such as CHO (J. Exp. Med. (1995) 108, 945), COS, 3T3, myeloma, BHK (baby hamster kidney), HeLa, Vero, amphibian cells such as Xenopus eggs Mother cells (Valle, et al., Nature (1981) 291, 358-340) or insect cells such as Sf9, Sf21, and Tn5 are known.
- CHO-DG44, CHO-DXB11, COS7 cells, and BHK cells are preferably used.
- CHO cells are particularly preferred for mass expression purposes.
- Introduction of a vector into a host cell can be performed by, for example, a calcium phosphate method, a DEAE dextran method, a method using a cationic liposome DOTAP (Boehringer Mannheim), an electroporation method, a lipofection method, or the like.
- yeasts such as the genus Saccharomyces, such as Saccharomyces cerevisiae, Saccharomyces pombe, filamentous fungi such as the genus Aspergillus, such as Aspergillus. Aspergillus niger) is known.
- Bacterial cells include E. coli (eg, JM109, DH5 ⁇ , HB101, etc.), and Bacillus subtilis is also known. It is possible to obtain the antigen of the present invention by culturing cells transformed with the DNA of the present invention in vitro and purifying them by a method commonly used by those skilled in the art.
- Mucosal adjuvant means a substance that enhances the immune response by administration to the mucosa.
- An immune adjuvant can be restated as an adjuvant, an adjuvant for a vaccine, an adjuvant for a vaccine, a vaccine adjuvant, an immune adjuvant composition, an adjuvant composition, an adjuvant composition, an immunostimulant, or an immunopotentiator, and any substance Even so, it means the immune adjuvant according to the invention.
- Mucosal adjuvants contained in the immunity material of the present invention include synthetic oligo CpG (Ameissmeet al., (2006) Vet. Immunol. Immunopathol. 110: 257-67), lectin, liposome, heat-labile E.
- Interleukin 12 is exemplified, but not limited thereto.
- the mucosal adjuvant contained in the immune material of the present invention is preferably a synthetic oligo CpG.
- the present invention relates to a method for reinducing immunity conferred by primary immunization by additionally administering an immune material containing an avian influenza virus antigen and a mucosal adjuvant effective by oral administration to an animal administered a vaccine against avian influenza. provide. Therefore, the immunity material of the present invention is used for booster immunization.
- the immunity material of the present invention is effective when administered to an individual whose antibody titer has already been increased by vaccine administration (for example, administration by injection) (boost immunization).
- vaccine administration for example, administration by injection
- the antibody titer of the individual can be further increased or maintained at a high level.
- a recombinant antigen and a mucosal adjuvant for example, by orally administering a recombinant antigen and a mucosal adjuvant to an individual who has already been inoculated with an oil vaccine as the first immunization and whose high level of antibody titer has already started to decrease, the antibody titer remarkably rises.
- Evaluation of the effectiveness of the vaccine is carried out by measuring the antibody titer by ELISA, measuring the HI titer, measuring the neutralizing antibody titer, clinical observation by virus challenge test using mice, etc. Methods are known to those skilled in the art.
- examples of animals to which immunity material is administered include humans, monkeys, birds, horses, pigs, and the like.
- the subject to which the immune material of the present invention is administered is a bird.
- the administration form of the immune material of the present invention is mucosal administration, preferably oral administration.
- the immunity material of the present invention can be formulated according to a conventional method (for example, Remington's Pharmaceuticals Science, latest edition, Mark Publishing Company, Easton, USA) and contains pharmaceutically acceptable carriers and additives together. There may be. Examples include surfactants, excipients, colorants, preservatives, stabilizers, buffers, suspending agents, isotonic agents, and the like, but are not limited thereto, and other conventional carriers can be used as appropriate.
- other components may be mixed and administered.
- other components include feeds for animals to be administered, additives (such as lactose) for improving palatability, and drinking water.
- recombinant antigens derived from influenza virus are mixed with normal baits so that the amount is about 5% by weight in the case of unpurified or crude products.
- Anti-protozoan disease oral vaccine by genetically modified plant International publication number: WO2005 / 116216]
- the dose can be selected, for example, from 3 to 14 times within 3 to 14 days and from 1 mcg (microgram, the same applies hereinafter) to 100 mcg of purified protein per bird. It is not necessarily limited to. About an administration interval, you may administer continuously and may administer at intervals. In the case of other animals, an amount converted to body weight or an amount converted per body surface area can be administered, but is not limited to these amounts.
- a suitable dose can be determined in consideration of the protective antigen expression level, optimal antibody production, the characteristics of the formulated feed, and the like.
- the use of the immune material of the present invention can also be expressed as (1) and (2) below.
- Example 1 Preparation of recombinant antigen protein derived from influenza virus and mucosal adjuvant
- the obtained cDNA fragment (base sequence SEQ ID NO: 1, amino acid sequence SEQ ID NO: 2) was digested with restriction enzymes SnaBI and NotI and inserted into pPIC9K plasmid (Multi-Copy Pichia Expression Kit: Invitrogen).
- the obtained HA expression plasmid was introduced into Pichia pastoris GS115 strain (Multi-Copy Pichia Expression Kit: Invitrogen). This transformation experiment was performed according to the instruction manual of Multi-Copy Pichia Expression Kit.
- clones expressing recombinant HA were Rabbit Polyclonal anti-Avian Influenza A Hemagglutinin antibody (Novus) and Goat anti-Rabbit IgG-heavy and light chain cross-adsorbed Antibody HRP Conjugated (Bethyl Laboratories And selected by Western blotting.
- the obtained HA-expressing yeast was inoculated into YPD medium (2% glucose, 1% yeast extract, 2% peptone) and cultured with shaking at 28 ° C. overnight.
- This culture solution was inoculated into MGY medium (1% glycerol, 0.00004% biotin, yeast nitrogen base (Invitrogen)) and cultured at 28 ° C. until the OD 600 reached 1.5 to 2.0 (16- 18 hours).
- Bacteria were collected by aseptically centrifuging this culture (2,000Xg, 5 minutes), and the resulting yeast cells were transformed into BMMY medium (0.5% methanol, 1% yeast extract, 2% peptone, 0.00004% Biotin, yeast nitrogen base (Invitrogen), 100 mM phosphate buffer, pH 6.0) were resuspended. This suspension was cultured with shaking at 28 ° C., and 16 hours later, methanol was aseptically added to 0.5% of the culture volume and further cultured for 6 hours. The obtained yeast cells were collected by centrifugation at 5,000 ⁇ g for 15 minutes and frozen at ⁇ 80 ° C.
- This crude extract was fractionated on a HiPrep 16/10 Q XL column (GE healthcare).
- the binding buffer was 20 mM Tris-Cl (pH 8.0), and the elution buffer was 20 mM Tris-Cl (pH 8.0) and 1 M NaCl, and elution was performed with a concentration gradient.
- Fractions containing recombinant HA were selected by Western blot using the same antibody as above.
- the collected fraction was concentrated and dialyzed by ultrafiltration (fractional molecular weight 30 kDa), and used after exchanging the buffer with 20 mM Tris-Cl (pH 8.0) and 150 mM NaCl.
- the purity of the obtained recombinant HA antigen was confirmed by 10% SDS-PAGE and Western blot (FIG. 1 (1-A)).
- the cDNA fragment of this NP gene (base sequence SEQ ID NO: 3, amino acid sequence SEQ ID NO: 4) was digested with restriction enzymes SalI and HindIII and inserted into plasmid vector pQE31 (Qiagen) for expression of recombinant proteins in E. coli. .
- This recombinant DNA was introduced into Escherichia coli M15 strain to prepare a recombinant Escherichia coli expressing recombinant NP. This recombination experiment was performed according to the instruction manual of Qiagen.
- the obtained NP-expressing recombinant Escherichia coli was inoculated into LB medium (1.0% Tryptone, 0.5% Yeast extract, 1.0% sodium chloride, ampicillin sodium salt 100mcg / ml, kanamycin sulfate 25mcg / ml) and shaken overnight at 37 ° C. Cultured. This preculture was inoculated into a 100-fold amount of fresh LB medium, and shaking culture was performed at 37 ° C. until OD 600 reached 0.6. IPTG was added (final concentration: 1 mM) so that the culture solution was enriched to the desired turbidity, and cultured overnight at 37 ° C. to induce NP protein expression.
- the cultured cells were collected by centrifugation at 5,000 ⁇ g for 20 minutes.
- the cells were resuspended in 20 mM Tris-HCl (pH 8.0) buffer, lysozyme was added to a final concentration of 0.4 mg / ml, and the lysis reaction was performed on ice for 30 minutes. After the reaction was completed, sodium deoxychlorate was added to a final concentration of 0.1%, and the mixture was kept at 37 ° C. for 30 minutes. This lysate was treated with Polytron (8,000 rpm, 2 minutes), and then centrifuged at 10,000 ⁇ g for 30 minutes.
- elution buffer (20 mM Tris-HCl, 0.5 M NaCl, 250 mM imidazole, pH 8.0) was added to the column four times to recover the recombinant NP.
- the obtained antigen protein was used after dialysis against 20 mM Tris-HCl (pH 8.0) and 0.5 M NaCl buffer.
- the purity of the obtained recombinant NP antigen was confirmed by 10% SDS-PAGE and Western blot (FIG. 1 (1-B)).
- the synthesized CpG-ODN was precipitated in ethanol, dissolved in sterilized PBS (137 mM NaCl, 8.1 mM Na 2 HPO 4 , 2.68 mM KCl, 1.47 mM KH 2 PO 4 ) and stored at ⁇ 20 ° C. until the start of the test.
- Example 2 Oral administration of recombinant antigen and mucosal adjuvant to oil-vaccinated chickens
- oil vaccine for avian influenza was inoculated against 4-week-old white leghorn (line-M).
- line-M 4-week-old white leghorn
- the avian influenza virus A / duck / Hokkaido / Vac-1 / 04 (H5N1) strain was used as a seed virus, and 0.2 ml each of 10 4 TCID50 prepared virus was injected into the allantoic cavity of 11-day-old embryonated chicken eggs. Inoculated. Incubation was performed at 34 ° C for 72 hours, and the infected allantoic fluid was recovered from chicken eggs that had been left at 4 ° C overnight.
- Beta-propiolactone was added to the supernatant obtained by centrifuging this allantoic fluid (3,000 Xg, 20 minutes) to a final concentration of 0.05% (v / v) at 4 ° C for 5 days. Inactivation treatment was performed. After inactivation, the HA value of the virus suspension was measured and adjusted to 5,120 HAU / ml with PBS to obtain an antigen solution. Add 65% light liquid paraffin, 1.4% (w / v) tetraoleic acid polyoxyethylene (40) sorbitol, 2.0% (w / v) sorbitan sesquioleate to this antigen solution, and use an emulsifier.
- venous blood was collected from test chickens every week, and the change in antibody titer was followed by ELISA. That is, recombinant HA or NP antigen diluted to a concentration of 0.1 mcg / mL with 0.05 M sodium carbonate buffer (Na 2 HCO 3 1.59 g / L, NaH 2 CO 3 2.93 g / L, pH 9.6) The solution was dispensed on a hole ELISA plate (manufactured by IWAKI) and allowed to stand at 4 ° C. overnight for coating.
- bovine serum albumin After washing the plate with PBS-T buffer (0.05% Tween20, 137 mM NaCl, 8.1 mM Na 2 HPO 4 , 2.68 mM KCl, 1.47 mM KH 2 PO 4 ), bovine serum albumin has a final concentration of 3% (w / v).
- PBS-T buffer 0.05% Tween20, 137 mM NaCl, 8.1 mM Na 2 HPO 4 , 2.68 mM KCl, 1.47 mM KH 2 PO 4
- the blocking solution added to the PBS-T buffer was dispensed onto the plate, and allowed to stand at 37 ° C. for 1 hour for blocking treatment. After blocking, wash with PBS-T buffer, and dilute antibody solution in PBS-T buffer so that bovine serum albumin has a final concentration of 0.3% (w / v).
- Serum of the test chicken diluted in two steps was dispensed onto a plate and allowed to react with the antigen by allowing it to stand at 37 ° C. for 1 hour.
- HRPO-labeled anti-chicken IgG ZYMED
- substrate solution Na 2 HPO 4 14.6g / L, citrate monohydrate 10.2g / L, ortho-phenylenediamine 1g / L, hydrogen peroxide 1ml / L
- Recombinant HA and NP antigens and mucosal adjuvant CpG-ODN were orally administered to chickens with decreased antibody titers (19 weeks after immunization with oil vaccine) after reaching the highest ELISA antibody titers.
- recombinant HA 100mcg, recombinant NP 100mcg, CpG-ODN 25mcg administration group recombinant HA 100mcg, recombinant NP 100mcg administration group
- PBS administration group So we prepared 4 birds in each group.
- Each antigen and CpG-ODN was prepared in PBS to a total liquid volume of 2 ml, and oral administration was performed by forced drinking using a syringe. Administration was carried out for 7 consecutive days, and the change in ELISA antibody titer was observed from the administration period to 1 week after completion. The test results are shown in FIG.
- the antibody titer could be re-induced by mixing orally administering recombinant HA, NP and CpG-ODN (FIG. 2). P ⁇ 0.05).
- re-induction of immunity against NP an antigen common to all subtypes of influenza A, was prominent (FIG. 2 (2-B), p ⁇ 0.01).
- the vaccine of the present invention was ineffective or weak when used for primary immunization, and was effective when used for booster immunization.
- an immunization material and a booster method capable of maintaining the immunity imparted by the first immunization with the oil vaccine at a high level for a longer period of time are provided.
- the immunization material and the booster method of the present invention enable vaccination for influenza prevention to be carried out simply and rationally.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
トリインフルエンザの予防手段として、ワクチンの投与による免疫誘導が有効であるため、わが国でも筋肉内接種による注射型オイルワクチンが製造および備蓄されている。このワクチンで付与した免疫をより長期間にわたって高いレベルで維持することができれば、非常に効果的な予防手段となり得る。しかしそのための既存の手段は有効性、価格、簡便さ、等の点で不十分であった。
例えば、インフルエンザワクチンの素材を作製する方法としては、「センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質(特許公開2000-253876)」や「ワクチンおよび遺伝子治療用の組換えインフルエンザウイルス(特許公開2003-528570)」、「リバースジェネティック法を利用しタンパク質ワクチンとトリインフルエンザワクチンを開発する方法(特許公開2007-282636)」などがあるが、いずれも追加免疫に言及するものではない。
また、A. D. Altsteinらは組換えNPのマウスに対する追加免疫を実施したが、その投与経路は腹腔投与である(Altstein et al. (2006) Arch. Virol.;151: 921-931)。さらに、G. Le Gall-Reculeらも鶏に対するオイルワクチンの追加免疫を実施しているが、その投与経路は皮下接種である(G. Le Gall-Recule et al. (2007) Avian Dis.;51: 490-494)。また、Y. Asahi-Ozakiらは、リバースジェネティクス法で作出した組換えウイルスを用いたHAワクチンを作製し、これを経鼻投与した試験を報告している(Y. Asahi-Ozaki et al. (2006) Microbes Infect.;8: 2706-2714)。
以上のように、組換えタンパク質抗原を用いた鶏に対する経口追加免疫の方法としては、有効な事例がなかった。
即ち本発明は、以下〔1〕~〔10〕を提供するものである。
〔1〕トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを含む、免疫材料。
〔2〕トリインフルエンザウイルス抗原が、組み換えHA抗原及び組み換えNP抗原である、〔1〕に記載の免疫材料。
〔3〕トリインフルエンザを予防するための、〔1〕又は〔2〕に記載の免疫材料。
〔4〕経口投与するための、〔1〕~〔3〕のいずれかに記載の免疫材料。
〔5〕追加免疫のための、〔1〕~〔4〕のいずれかに記載の免疫材料。
〔6〕トリインフルエンザワクチンを投与された動物に対し、〔1〕~〔5〕のいずれかに記載の免疫材料を追加投与し、初回免疫で付与された免疫を再誘導させる方法。
〔7〕動物が鳥である、〔6〕に記載の方法。
〔8〕追加投与が経口投与である、〔6〕又は〔7〕に記載の方法。
〔9〕トリインフルエンザに対するワクチンを投与された動物において初回免疫で付与された免疫を再誘導させるための薬剤の製造における、〔1〕~〔5〕に記載の免疫材料の使用。
〔10〕トリインフルエンザに対するワクチンを投与された動物において初回免疫で付与された免疫を再誘導させる方法に使用するための、〔1〕~〔5〕に記載の免疫材料の使用。
A型インフルエンザはHAの型(およびNAの型)により分類されるが、現在までに見出された高病原性トリインフルエンザはH5、H7亜型に限定されている。これらの亜型ウイルスは、感染を繰り返すうちに強毒化する場合もあり、強毒型、弱毒型に関わらず警戒が必要とされる。
(a)配列番号:2に記載のアミノ酸配列を含むタンパク質;
(b)配列番号:1に記載の塩基配列のコード領域を含む核酸によりコードされるタンパク質;
(c)配列番号:2に記載のアミノ酸配列において1若しくは複数のアミノ酸が置換、欠失、挿入、および/または付加したアミノ酸配列からなり、配列番号:2に記載のアミノ酸配列を含むタンパク質と機能的に同等なタンパク質;
(d)配列番号:1に記載の塩基配列を含む核酸とストリンジェントな条件下でハイブリダイズする核酸によりコードされるタンパク質であって、配列番号:2に記載のアミノ酸配列を含むタンパク質と機能的に同等なタンパク質。
(a)配列番号:4に記載のアミノ酸配列を含むタンパク質;
(b)配列番号:3に記載の塩基配列のコード領域を含む核酸によりコードされるタンパク質;
(c)配列番号:4に記載のアミノ酸配列において1若しくは複数のアミノ酸が置換、欠失、挿入、および/または付加したアミノ酸配列からなり、配列番号:4に記載のアミノ酸配列を含むタンパク質と機能的に同等なタンパク質;
(d)配列番号:3に記載の塩基配列を含む核酸とストリンジェントな条件下でハイブリダイズする核酸によりコードされるタンパク質であって、配列番号:4に記載のアミノ酸配列を含むタンパク質と機能的に同等なタンパク質。
改変されるアミノ酸の数は、典型的には50アミノ酸以内であり、好ましくは30アミノ酸以内であり、さらに好ましくは5アミノ酸以内(例えば、1アミノ酸)であると考えられる。
また、非保存的置換によりタンパク質の活性などをより上昇(例えば恒常的活性化型タンパク質などを含む)させることも考えられる。
ハイブリダイゼーションを利用することによって、たとえば配列番号:2又は4に記載のアミノ酸配列を含むタンパク質以外のインフルエンザウイルス抗原のホモログをコードするDNAの単離が可能である。
他の動物の場合も、体重に換算した量、あるいは体表面積あたりに換算した量を投与することができるが、これらの量に限定されない。好適な投与量は、防御抗原発現量や至適抗体産生、配合飼料の性質などを考慮して決定することができる。
(1)トリインフルエンザに対するワクチンを投与された動物において初回免疫で付与された免疫を再誘導させるための薬剤の製造における、トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを含む免疫材料の使用。
(2)トリインフルエンザに対するワクチンを投与された動物において初回免疫で付与された免疫を再誘導させる方法に使用するための、トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを含む免疫材料の使用。
[実施例1]インフルエンザウイルスを由来とする組換え抗原タンパクおよび粘膜アジュバントの作成
A/duck/Mongolia/54/01 (H5N2)株のHAタンパク質のうちN末端より17番目から528番目のアミノ酸をコードする遺伝子を逆転写PCR法により増幅した。
すなわち、プライマーとして5’-GCC CTA CGT AGA CCA AAT TTG CAT TGG TTA C-3’(配列番号:5)および5’-ATA GTT TAG CGG CCG CTT A TAT TTG GTA AGT TCC-3’(配列番号:6)を使用し、One Step RNA PCR kit (AMV) (TaKaRa社)で逆転写PCRを行った。
得られたcDNA断片(塩基配列 配列番号:1、アミノ酸配列 配列番号:2)を制限酵素SnaBI、NotIを用いて消化しpPIC9Kプラスミド(Multi-Copy Pichia Expression Kit: Invitrogen社)に挿入した。得られたHA発現プラスミドをPichia pastoris GS115株(Multi-Copy Pichia Expression Kit: Invitrogen社)に導入した。この形質転換実験は、Multi-Copy Pichia Expression Kitの取扱説明書に準じて実施した。
回収した画分は、限外ろ過 (分画分子量30kDa)による濃縮と透析を行い、20mM Tris-Cl (pH8.0)、150mM NaClにバッファー交換して使用した。得られた組換えHA抗原は、10% SDS-PAGEおよびウェスタンブロットで精製度を確認した (図1(1-A))。
A/duck/Hokkaido/9/99 (H9N2)株のNP遺伝子を、5’-ACG CGT CGA CGC GCT TCA AGG CAC CAA ACG ATC-3’(配列番号:7)および5’-CCC AAG CTT CTC CTC TGC ATT GTC TCC GAA-3’(配列番号:8)を使用し、One Step RNA PCR kit (AMV) (TaKaRa社)を用いた逆転写PCRで入手した。
このNP遺伝子のcDNA断片(塩基配列 配列番号:3、アミノ酸配列 配列番号:4)を、制限酵素SalIおよびHindIIIで消化し、大腸菌での組換えタンパク質発現用プラスミドベクターpQE31(Qiagen社)に挿入した。この組換えDNAをEscherichia coli M15株に導入し、組換えNPを発現する組換え大腸菌を作成した。この組換え実験は、Qiagen社の取扱説明書に準じて実施した。
粘膜アジュバントとして、すでに経口法での免疫賦活効果が報告されたCpG配列5'-GTC GTT GTC GTT GTC GTT-3' (Ameiss et al., (2006) Vet. Immunol. Immunopathol. 110:257-67、配列番号:9)を使用した。このDNA (CpG-oligo dinucleotide、以下CpG-ODN)の合成をOperon社に依頼するにあたり、消化耐性を高めるために、リン酸骨格の酸素原子を硫黄原子に置換した。
合成したCpG-ODNはエタノール沈殿後、滅菌済みPBS (137mM NaCl、8.1mM Na2HPO4、2.68mM KCl、1.47mM KH2PO4)に溶解し、試験開始まで-20℃で保存した。
初回免疫として、4週齢の白色レグホン(line-M)に対してトリインフルエンザ用オイルワクチンを接種した。具体的には、トリインフルエンザウイルスA/duck/Hokkaido/Vac-1/04 (H5N1)株を種ウイルスとし、104TCID50に調製したウイルスを0.2mlずつ11日齢の発育鶏卵の尿膜腔内に接種した。34℃で72時間の培養を行い、4℃に一晩静置した鶏卵より感染尿膜腔液を回収した。この尿膜腔液を遠心分離 (3,000Xg、20分)することで得られた上清に、終濃度0.05% (v/v)になるようbeta-propiolactoneを添加して4℃で5日間の不活化処理を行った。不活化後ウイルス浮遊液のHA価を測定し、PBSで5,120 HAU/mlに調製して抗原液とした。この抗原液にlight liquid paraffinを65%、tetraoleic acid polyoxyethylene (40) sorbitolを1.4% (w/v)、sorbitan sesquioleateを2.0% (w/v)の割合になるよう加えて、乳化機を用いて (循環流量4L/min、8,000rpm、0.5kPa)乳化したものをワクチンとした。このオイルワクチンのHA価は1,024 HAU/mlであり、鶏1羽あたり0.5ml筋肉内接種を行った。すなわち、1羽あたりの投与抗原量は512HAUである。
試験結果を図2に示す。
Claims (8)
- トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを含む、免疫材料。
- トリインフルエンザウイルス抗原が、組み換えHA抗原及び組み換えNP抗原である、請求項1に記載の免疫材料。
- トリインフルエンザを予防するための、請求項1又は2に記載の免疫材料。
- 経口投与するための、請求項1~3のいずれかに記載の免疫材料。
- 追加免疫のための、請求項1~4のいずれかに記載の免疫材料。
- トリインフルエンザワクチンを投与された動物に対し、請求項1~5のいずれかに記載の免疫材料を追加投与し、初回免疫で付与された免疫を再誘導させる方法。
- 動物が鳥である、請求項6に記載の方法。
- 追加投与が経口投与である、請求項6又は7に記載の方法。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2734643A CA2734643A1 (en) | 2008-08-18 | 2009-08-13 | Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration |
JP2010525677A JP5343079B2 (ja) | 2008-08-18 | 2009-08-13 | トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 |
AU2009283557A AU2009283557B2 (en) | 2008-08-18 | 2009-08-13 | Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration |
EP09808225.8A EP2329845A4 (en) | 2008-08-18 | 2009-08-13 | BIRD GRAPEVIRUS ANTIGEN AND BOOSTER IMMUNIZATION PROCEDURE FOR BIRD FLUID VACCINE IN COMBINATION WITH A MUCOSAL ADJUVAN WITH EFFICACY THROUGH ORAL ADMINISTRATION |
US13/059,777 US20110195091A1 (en) | 2008-08-18 | 2009-08-13 | Avian Influenza Virus Antigen, and Booster Immunization Method for Avian Influenza Vaccine in Combination with Mucosal Adjuvant Which is Effective Through Oral Administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-210021 | 2008-08-18 | ||
JP2008210021 | 2008-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010021289A1 true WO2010021289A1 (ja) | 2010-02-25 |
Family
ID=41707167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/064285 WO2010021289A1 (ja) | 2008-08-18 | 2009-08-13 | トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110195091A1 (ja) |
EP (1) | EP2329845A4 (ja) |
JP (2) | JP5343079B2 (ja) |
AU (1) | AU2009283557B2 (ja) |
CA (1) | CA2734643A1 (ja) |
WO (1) | WO2010021289A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011136738A1 (en) | 2010-04-30 | 2011-11-03 | Temasek Life Sciences Laboratory Limited | Universal vaccine against h5n1 lineages |
CN102905726A (zh) * | 2010-06-03 | 2013-01-30 | 葛兰素史密丝克莱恩生物有限公司 | 包含抗原和Toll样受体激动剂的口服疫苗 |
JP2014516533A (ja) * | 2011-05-26 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
JP2014516534A (ja) * | 2011-05-26 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
US9364531B2 (en) | 2010-12-30 | 2016-06-14 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103127501A (zh) * | 2013-03-27 | 2013-06-05 | 南京农业大学 | 一种用于鸡禽流感鼻腔免疫的人工合成佐剂 |
US20240041760A1 (en) * | 2021-02-08 | 2024-02-08 | Intervet Inc. | Vaccination for protecting poultry against a poultry pathogen |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000253876A (ja) | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
JP2003528570A (ja) | 1999-04-06 | 2003-09-30 | ウイスコンシン・アルムニ・リサーチ・フアンデーシヨン | ワクチンおよび遺伝子療法用の組換えインフルエンザウイルス |
WO2005116216A1 (ja) | 2004-05-31 | 2005-12-08 | The Kitasato Institute | 遺伝子組換え植物による抗原虫病経口ワクチン |
JP2005539039A (ja) * | 2002-08-27 | 2005-12-22 | ダウ アグロサイエンシィズ エルエルシー | 鳥類及び家禽類におけるアジュバントとしてのエシェリシア・コリ熱不安定性毒素の使用 |
WO2007053446A2 (en) * | 2005-10-28 | 2007-05-10 | Boehringer Ingelheim Vetmedica, Inc | Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species |
JP2007526215A (ja) * | 2003-05-05 | 2007-09-13 | ダウ アグロサイエンス リミテッド ライアビリティー カンパニー | トランスジェニック植物細胞に由来する安定な免疫予防的および治療的組成物ならびにその産生方法 |
JP2007528411A (ja) * | 2004-03-09 | 2007-10-11 | カイロン コーポレイション | インフルエンザウイルスワクチン |
JP2007282636A (ja) | 2006-04-14 | 2007-11-01 | Healthbanks Biotech Co Ltd | リバースジェネティック法を利用しタンパク質ワクチンとトリインフルエンザワクチンを開発する方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512421A (ja) * | 2005-08-15 | 2009-03-26 | ヴァクシン インコーポレイテッド | 非複製性ベクターワクチン投与による鳥類への免疫方法 |
CN100336823C (zh) * | 2006-02-23 | 2007-09-12 | 扬州大学 | 一种鸡特异性的CpG ODN及其应用 |
-
2009
- 2009-08-13 EP EP09808225.8A patent/EP2329845A4/en not_active Withdrawn
- 2009-08-13 JP JP2010525677A patent/JP5343079B2/ja not_active Expired - Fee Related
- 2009-08-13 CA CA2734643A patent/CA2734643A1/en not_active Abandoned
- 2009-08-13 AU AU2009283557A patent/AU2009283557B2/en not_active Ceased
- 2009-08-13 WO PCT/JP2009/064285 patent/WO2010021289A1/ja active Application Filing
- 2009-08-13 US US13/059,777 patent/US20110195091A1/en not_active Abandoned
-
2013
- 2013-06-18 JP JP2013127162A patent/JP2013237673A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000253876A (ja) | 1999-03-08 | 2000-09-19 | Dnavec Research Inc | センダイウイルスベクターを用いたワクチンおよびワクチンタンパク質 |
JP2003528570A (ja) | 1999-04-06 | 2003-09-30 | ウイスコンシン・アルムニ・リサーチ・フアンデーシヨン | ワクチンおよび遺伝子療法用の組換えインフルエンザウイルス |
JP2005539039A (ja) * | 2002-08-27 | 2005-12-22 | ダウ アグロサイエンシィズ エルエルシー | 鳥類及び家禽類におけるアジュバントとしてのエシェリシア・コリ熱不安定性毒素の使用 |
JP2007526215A (ja) * | 2003-05-05 | 2007-09-13 | ダウ アグロサイエンス リミテッド ライアビリティー カンパニー | トランスジェニック植物細胞に由来する安定な免疫予防的および治療的組成物ならびにその産生方法 |
JP2007528411A (ja) * | 2004-03-09 | 2007-10-11 | カイロン コーポレイション | インフルエンザウイルスワクチン |
WO2005116216A1 (ja) | 2004-05-31 | 2005-12-08 | The Kitasato Institute | 遺伝子組換え植物による抗原虫病経口ワクチン |
WO2007053446A2 (en) * | 2005-10-28 | 2007-05-10 | Boehringer Ingelheim Vetmedica, Inc | Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species |
JP2007282636A (ja) | 2006-04-14 | 2007-11-01 | Healthbanks Biotech Co Ltd | リバースジェネティック法を利用しタンパク質ワクチンとトリインフルエンザワクチンを開発する方法 |
Non-Patent Citations (27)
Title |
---|
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY |
ALTSCHUL, S.F. ET AL., J. MOL. BIOL., vol. 215, no. 3, 1990, pages 403 - 10 |
ALTSCHUL, S.F. ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
ALTSCHUL, S.F.; GISH, W, METH. ENZYMOL., vol. 266, 1996, pages 460 - 480 |
ALTSTEIN ET AL., ARCH. VIROL., vol. 151, 2006, pages 921 - 931 |
AMEISS ET AL., VET. IMMUNOL. IMMUNOPATHOL., vol. 110, 2006, pages 257 - 67 |
BAGCHI, CMAJ, vol. 178, 2008, pages 1415 |
CRAWFORD,J.M. ET AL.: "Molecular characterization of the hemagglutinin gene and oral immunization with a waterfowl-origin avian influenza virus", AVIAN DIS, vol. 42, no. 3, 1998, pages 486 - 96, XP009087613 * |
ELIASSON D. G. ET AL., VACCINE, vol. 26, 2008, pages 1243 - 52 |
G. LE GALL-RECULE ET AL., AVIAN DIS., vol. 51, 2007, pages 490 - 494 |
HIROSE, S. ET AL., PROC. NATL. ACAD. SCI. USA., vol. 79, 1982, pages 7258 - 7260 |
HORTHONGKHAM N. ET AL., J. IMMUNE. BASED THER. VACCINES, vol. 5, 2007, pages 10 |
HULEATT J. W ET AL., VACCINE, vol. 26, 2008, pages 201 - 14 |
ILYINSKII P. O. ET AL., VACCINE, vol. 26, 2008, pages 2177 - 85 |
ISAKA M. ET AL., MICROBIOL. IMMUNOL., vol. 52, 2008, pages 55 - 63 |
J. EXP. MED., vol. 108, 1995, pages 945 |
KARLIN, S.; S. F. ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 68 |
KARLIN, S.; S. F. ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 7 |
KRAMER W.; FRITZ HJ., METHODS IN ENZYMOL., vol. 154, 1987, pages 350 - 367 |
OHBA K. ET AL., VACCINE, vol. 25, 2007, pages 4291 - 300 |
ROY S. ET AL., VACCINE, vol. 25, 2007, pages 6845 - 51 |
SYLTE M. J. ET AL., VACCINE, vol. 25, 2007, pages 3763 - 72 |
VALLE ET AL., NATURE, vol. 291, 1981, pages 358 - 340 |
WEBSTER R. G. ET AL., VACCINE, vol. 9, 1991, pages 303 - 8 |
WRIGHT, N. ENGL. J. MED., vol. 358, 2008, pages 2540 - 2543 |
Y. ASAHI-OZAKI ET AL., MICROBES INFECT., vol. 8, 2006, pages 2706 - 2714 |
ZANVIT P. ET AL., IMMUNOL. LETT., vol. 115, 2008, pages 144 - 52 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011136738A1 (en) | 2010-04-30 | 2011-11-03 | Temasek Life Sciences Laboratory Limited | Universal vaccine against h5n1 lineages |
CN102905726A (zh) * | 2010-06-03 | 2013-01-30 | 葛兰素史密丝克莱恩生物有限公司 | 包含抗原和Toll样受体激动剂的口服疫苗 |
JP2013527218A (ja) * | 2010-06-03 | 2013-06-27 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 抗原およびToll様受容体アゴニストを含有する経口ワクチン |
US9364531B2 (en) | 2010-12-30 | 2016-06-14 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
JP2014516533A (ja) * | 2011-05-26 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
JP2014516534A (ja) * | 2011-05-26 | 2014-07-17 | インターベット インターナショナル ベー. フェー. | 免疫刺激性オリゴデオキシヌクレオチド |
US9315814B2 (en) | 2011-05-26 | 2016-04-19 | Intervet Inc. | Immunostimulatory oligodeoxynucleotides |
Also Published As
Publication number | Publication date |
---|---|
JP5343079B2 (ja) | 2013-11-13 |
EP2329845A1 (en) | 2011-06-08 |
CA2734643A1 (en) | 2010-02-25 |
AU2009283557A1 (en) | 2010-02-25 |
EP2329845A4 (en) | 2013-08-14 |
AU2009283557B2 (en) | 2013-01-17 |
JP2013237673A (ja) | 2013-11-28 |
US20110195091A1 (en) | 2011-08-11 |
JPWO2010021289A1 (ja) | 2012-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lee et al. | New vaccines against influenza virus | |
JP6294828B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
JP5343079B2 (ja) | トリインフルエンザウイルス抗原及び経口投与で有効な粘膜アジュバントを併用したトリインフルエンザワクチンの追加免疫方法 | |
US8128938B1 (en) | Influenza virus vaccine composition and methods of use | |
JP6643981B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
JP6735269B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
Whittaker | Intracellular trafficking of influenza virus: clinical implications for molecular medicine | |
JP7317047B2 (ja) | インフルエンザウイルスワクチン及びその使用 | |
EP3494989A1 (en) | Composite antigenic sequences and vaccines | |
US20140255343A1 (en) | Dna vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the h5 haemagglutinin of an influenza virus and use of the dna vaccine | |
JP2022530439A (ja) | 組換えインフルエンザ抗原 | |
KR20060035602A (ko) | 말-2인플루엔자 바이러스의 ha1을 발현하는 dna 백신 | |
JP5730204B2 (ja) | インフルエンザm2由来の改変ペプチドワクチン | |
JP2018052953A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
KR20220082042A (ko) | 인플루엔자 바이러스 백신 및 이의 용도 | |
Kawai et al. | Vaccine effect of recombinant single-chain hemagglutinin protein as an antigen | |
JP7167088B2 (ja) | インフルエンザウイルスワクチンおよびその使用 | |
US20230055468A1 (en) | Broadly reactive viral antigens as immunogens, compositions and methods of use thereof | |
Hussein et al. | Protective efficacy of a prime-boost protocol using H5-DNA plasmid as prime and inactivated H5N2 vaccine as the booster against the Egyptian avian influenza challenge virus | |
KR101672719B1 (ko) | 바이러스 중화항원 단백질 발현을 위한 보르데텔라 백일해 균주 및 이를 이용한 면역원성 조성물 | |
CN116925195A (zh) | 一种基于新型冠状病毒的mRNA疫苗 | |
EA046012B1 (ru) | Вакцины против вируса гриппа и пути их применения | |
KR20130001559A (ko) | 넓은 범위의 교차 방어능력을 갖는 신규한 보강 인플루엔자 백신 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09808225 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010525677 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2734643 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009283557 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1784/CHENP/2011 Country of ref document: IN Ref document number: 2009808225 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009283557 Country of ref document: AU Date of ref document: 20090813 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13059777 Country of ref document: US |